"Receptors, Somatomedin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that bind somatomedins and trigger intracellular changes which influence the behavior of cells. Studies have disclosed two types of receptors for this family of peptide hormones. The type I receptor is homologous to the insulin receptor and has tyrosine kinase activity. The type II receptor is identical to the mannose-6-phosphate receptor which is important in trafficking of lysosomal enzymes.
| Descriptor ID |
D017451
|
| MeSH Number(s) |
D12.776.543.750.750.400.780
|
| Concept/Terms |
Receptors, Somatomedin- Receptors, Somatomedin
- Insulin-Like Growth Factor Receptors
- Insulin Like Growth Factor Receptors
- Somatomedin Receptor
- Receptor, Somatomedin
- Somatomedin Receptors
- Insulin-Like Growth Factor Receptor
- Insulin Like Growth Factor Receptor
- Receptors, Insulin-Like Growth Factors
- Receptors, Insulin Like Growth Factors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Somatomedin".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Somatomedin".
This graph shows the total number of publications written about "Receptors, Somatomedin" by people in this website by year, and whether "Receptors, Somatomedin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 3 | 0 | 3 |
| 2016 | 3 | 1 | 4 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Somatomedin" by people in Profiles.
-
Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res. 2018 10 15; 24(20):5165-5177.
-
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
-
Anti-M?llerian Hormone (AMH) May Stall Ovarian Cortex Function Through Modulation of Hormone Receptors Other Than the AMH Receptor. Reprod Sci. 2018 08; 25(8):1218-1223.
-
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017 10 03; 18(10):816-826.
-
Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Invest New Drugs. 2017 Oct; 35(5):545-555.
-
Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. 2017 Jan 03; 8(1):1814-1844.
-
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
-
Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology. 2016; 91(2):90-100.
-
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016 06; 157(2):253-265.
-
Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc Natl Acad Sci U S A. 2016 Feb 23; 113(8):E1016-25.